Literature DB >> 23389876

Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain.

Roberto Labianca1, Piercarlo Sarzi-Puttini, Stefano Maria Zuccaro, Paolo Cherubino, Renato Vellucci, Diego Fornasari.   

Abstract

Chronic pain is a debilitating condition that is associated with many common diseases; this places a major burden on the healthcare system. There are currently numerous analgesic agents available for the treatment of chronic pain. In general, the oral non-opioid analgesic, paracetamol, is recommended for the initial treatment of mild to moderate pain. Therapeutic doses of paracetamol do not appear to result in hepatotoxicity, although overdose may lead to acute liver failure. Current data suggest that paracetamol has acceptable gastrointestinal tolerability. Another class of non-opioid analgesic with confirmed efficacy for the treatment of chronic mild to moderate pain are non-steroidal anti-inflammatory drugs (NSAIDs), although this efficacy is offset by the potential of adverse gastrointestinal events. In particular, non-selective NSAIDs, also known as cyclooxygenase (COX) inhibitors, carry an increased risk of serious upper gastrointestinal complications, including ulcers, perforation and bleeding. The introduction of COX-2 inhibitors provided a NSAID-based option with improved gastrointestinal safety, but increased risk of cardiovascular effects. Opioids are powerful analgesic agents used to treat moderate to severe chronic pain. However, treatment with opioids is associated with a number of common adverse effects, including constipation, nausea or vomiting, pruritus, somnolence or cognitive impairment, dry mouth, tolerance or dependence and urinary retention. Although there are multiple strategies in place to manage adverse events that arise from both non-opioid and opioid analgesic therapy, a better understanding of the mechanisms involved in the development of specific drug-related adverse effects is required along with proper prescribing practices and adequate physician/patient education. Balanced against the adverse effects of pain management medications, there is a need to be mindful of the widespread, often serious, adverse consequences of poorly managed pain itself.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23389876     DOI: 10.2165/11630080-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  8 in total

1.  Effect of Mobile Device-Assisted N-of-1 Trial Participation on Analgesic Prescribing for Chronic Pain: Randomized Controlled Trial.

Authors:  David D Odineal; Maria T Marois; Deborah Ward; Christopher H Schmid; Rima Cabrera; Ida Sim; Youdan Wang; Barth Wilsey; Naihua Duan; Stephen G Henry; Richard L Kravitz
Journal:  J Gen Intern Med       Date:  2019-08-28       Impact factor: 5.128

Review 2.  Neuronal and glial factors contributing to sex differences in opioid modulation of pain.

Authors:  Dayna L Averitt; Lori N Eidson; Hillary H Doyle; Anne Z Murphy
Journal:  Neuropsychopharmacology       Date:  2018-06-23       Impact factor: 7.853

3.  Neurochemical phenotype and function of endomorphin 2-immunopositive neurons in the myenteric plexus of the rat colon.

Authors:  Jun-Ping Li; Xi-Yu Wang; Chang-Jun Gao; Yong-Hui Liao; Juan Qu; Zhong-Yi He; Ting Zhang; Guo-Du Wang; Yun-Qing Li
Journal:  Front Neuroanat       Date:  2014-12-16       Impact factor: 3.856

Review 4.  A Comprehensive Review of Alternative Therapies for the Management of Chronic Pain Patients: Acupuncture, Tai Chi, Osteopathic Manipulative Medicine, and Chiropractic Care.

Authors:  Ivan Urits; Ruben H Schwartz; Vwaire Orhurhu; Nishita V Maganty; Brian T Reilly; Parth M Patel; Christopher Wie; Alan D Kaye; Ken F Mancuso; Aaron J Kaye; Omar Viswanath
Journal:  Adv Ther       Date:  2020-11-12       Impact factor: 3.845

5.  Effects of Ketoprofen and Morphine on Pain-Related Depression of Nestlet Shredding in Male and Female Mice.

Authors:  Jamani B Garner; Laura S Marshall; Nathaniel M Boyer; Vinaya Alapatt; Laurence L Miller
Journal:  Front Pain Res (Lausanne)       Date:  2021-06-08

Review 6.  Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials.

Authors:  Di Zhao; Ling-Feng Zeng; Gui-Hong Liang; Jian-Ke Pan; Ming-Hui Luo; Yan-Hong Han; Jun Liu; Wei-Yi Yang
Journal:  EFORT Open Rev       Date:  2022-07-05

7.  Preferred Communication Strategies Used by Physical Therapists in Chronic Pain Rehabilitation: A Qualitative Systematic Review and Meta-Synthesis.

Authors:  Chelsea R Chapman; Nathan T Woo; Katrina S Maluf
Journal:  Phys Ther       Date:  2022-09-04

8.  MicroRNAs Are Involved in the Development of Morphine-Induced Analgesic Tolerance and Regulate Functionally Relevant Changes in Serpini1.

Authors:  Jenica D Tapocik; Kristin Ceniccola; Cheryl L Mayo; Melanie L Schwandt; Matthew Solomon; Bi-Dar Wang; Truong V Luu; Jacqueline Olender; Thomas Harrigan; Thomas M Maynard; Greg I Elmer; Norman H Lee
Journal:  Front Mol Neurosci       Date:  2016-03-24       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.